All News
Filter News
Found 2,999 articles
-
Essential Pharma acquires Renaissance Pharma Ltd with its clinical stage immunotherapy for the treatment of high-risk neuroblastoma
4/9/2024
Essential Pharma announces that it has completed the acquisition of the entire issued share capital of Renaissance Pharma Ltd.
-
Jacobio Pharma to Present Data of PARP7 Inhibitor and P53 Reactivator at the 2024 AACR Annual Meeting
4/9/2024
Jacobin Pharma (1167.HK) today announced that the company will present the results of two preclinical evaluation of PARP7 inhibitor JAB-26766 and p53 Y220C reactivator JAB-30355 in form of the abstract during the American Association for Cancer Research (AACR) Annual Meeting 2024 (the "AACR 2024") from April 5 to 10, 2024.
-
MAIWEIJIAN, First Approved Biosimilar of Denosumab (120mg) in China
4/8/2024
Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that Denosumab Injection (trade name: MAIWEIJIAN, R&D code: 9MW0321) developed by its wholly-owned subsidiary T-mab has officially obtained the marketing authorization approval by National Medical Products Administration (NMPA) (Drug Approval Number: [GYZZ]S20240010).
-
Phanes Therapeutics' PT217 granted Fast Track Designation by the FDA
4/8/2024
Phanes Therapeutics, Inc. (Phanes) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PT217 for the treatment of patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression following platinum chemotherapy with or without a checkpoint inhibitor.
-
Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints
4/8/2024
Shanghai Henlius Biotech, Inc. and Organon announced that the phase 3 comparative clinical trial for the investigational Prolia® and Xgeva® biosimilar HLX14 met the primary endpoints.
-
Antengene Presents Four Preclinical Posters at AACR 2024
4/6/2024
Antengene Corporation Limited announced the presentation of four preclinical posters at the 2024 American Association for Cancer Research Annual Meeting, taking place from April 5th to April 10th at the San Diego Convention Center in San Diego, California, the United States.
-
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference
4/5/2024
I-Mab announced that management will present at the 23rd Annual Needham Virtual Healthcare Conference on April 11, 2024.
-
Precision Biologics to Present at the American Association for Cancer Research (AACR) Annual Meeting on April 8th, 2024
4/5/2024
Precision Biologics, Inc. reports its lead monoclonal antibody, NEO-201, targets circulating human naïve regulatory T cells (Tregs) in both healthy donors and cancer patients.
-
Invivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million
4/4/2024
Invivyd, Inc., a biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, announced that PEMGARDA™ is now available for purchase in the U.S.
-
Florida Cancer Specialists & Research Institute Shares Pharmacy Expertise To Advance Medically Integrated Oncology Care
4/3/2024
Florida Cancer Specialists & Research Institute, LLC leaders and pharmacy experts will share insights and best practices in specialty pharmacy operations and dispensing that are contributing to positive patient outcomes at the NCODA 2024 Spring Forum in Dallas.
-
Avalo Therapeutics Appoints Biotech Leaders to Board of Directors
4/2/2024
Avalo Therapeutics, Inc. announced the addition of multiple biotech leaders to its Board of Directors.
-
Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status
4/2/2024
Innovent Biologics, Inc. and HUTCHMED Limited jointly announce that the New Drug Application for the combination of sintilimab and fruquintinib for the treatment of patients with advanced endometrial cancer with pMMR[1] or non-MSI-H[2] tumors that have failed prior systemic therapy but are not candidates for curative surgery or radiation has been accepted and granted priority review by the China National Medical Products Administration.
-
OSE Immunotherapeutics Announces Peer-Reviewed Publication on Novel Myeloid Immune Checkpoint CLEC-1 in Journal of Immunology
4/2/2024
OSE Immunotherapeutics SA announced the publication of novel data in the peer-reviewed Journal of Immunology on a first-in-class research program with CLEC-1, its novel myeloid immune checkpoint target for cancer immunotherapy.
-
Jacobio Pharma Announces 2023 Annual Results
3/29/2024
Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced its 2023 annual results.
-
Avalo Reports 2023 Financial Results and Provides Business Updates
3/29/2024
Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced business updates and year-end financial results for 2023.
-
CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Business and Financial Results
3/28/2024
CASI Pharmaceuticals, Inc. reported business and financial results for the year ended December 31, 2023, and provided an update on key highlights for 2023.
-
Dyadic Reports 2023 Full Year Results and Recent Company Progress
3/28/2024
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI) today announced its financial result for the year end 2023 and highlighted recent Company progress.
-
Innovent Dosed First Participant in Phase 3 Clinical Study (Neoshot) of IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy
3/27/2024
Innovent Biologics, Inc. announces that the first participant has been successfully dosed with IBI310 in combination with sintilimab in a randomized, controlled, multicenter Phase 3 clinical trial, for resectable MSI-H/dMMR[1] colon cancer neoadjuvant therapy.
-
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million
3/27/2024
Avalo Therapeutics, Inc. announced it has acquired a Phase 2-ready anti-IL-1β mAb, which it refers to as AVTX-009, through the acquisition of privately held AlmataBio, Inc.
-
OSE Immunotherapeutics Reports Full Year 2023 Financial Results and Provides Business Strategy Update
3/27/2024
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today reported its consolidated annual financial results for 2023 and provided an update on key proprietary clinical and preclinical achievements, on ongoing collaboration and licensing agreements, as well as on the 2024 Company’s outlook.